Mortality in joint replacements in RA vs OA at 30 days #ACR19 #ACR @RheumNow Abstract 2872. RA more readmission 2 x higher and increased mortality https://t.co/XjlpzZPUNl

Early RA is getting better over time periods but maybe just ACPA positive for sustained drug free remission. Counter intuitive. But still more in ACPA beg but less improvement Interesting. #ACR #ACR19 @RheumNow abstract 2871 https://t.co/JQJ90wxksi

Treatment approach for skin disease in systemic sclerosis SSc from Hummers L. Polymerase 3 antibody predictive of skin progression and MMF benecial for treating SSc skin disease #ACR19 @RheumNow https://t.co/rdHOS9S23u

#ACR19 Abst#2878 #ACRbest - Tildrakizumab (IL23i) RCT Good ACR20 (80% v 51%, NNT ~3) regardless of dose; great safety profile. Curiously high PLBO response, expectation bias? PASI75 phenomenal per usual (80% v 17% plbo, NNT 1-2) Need IL23/IL17/TNF comparative study! @RheumNow https://t.co/uEGvsD8KVb

#ACR19 Guidelines for OA: my take home is this truly astonishing funnel plot Virtually zero small negative studies and dozens of small positive studies Clear trend toward NO effect w/more precision in trial Publication bias et al. in action!! @RheumNow https://t.co/65nKzghobz

@RheumNow #acr19 abs2876 GODACT ph3 trial: glimumab+MTX improves clinical& MRI dactylitis scores better than MTX mono. mean MTX dose in the golimumab+ MTX group 16.3mg/wk & 19.2mg/wk in the MTX mono group . Also better DAS28,DAPSA,PASDAS& tNAPSI at wk 24 in golimumab group

Practical tips for Raynauds in curbside consults. If Raynauds onsets at age less than 40 and no symptoms or signs of secondary causes such as CTD and normal nailfold capillaries likely no investigations are needed 5T118 #ACR #ACR19 #Scleroderma @RheumNow https://t.co/59gnI5ECNZ

”...too much attention to developing the memory and not enough to developing the mind.” William J. Mayo, 1933. Couldn't have said it better myself. Remains a challenge in #MedEd to this day. #ACR19 @RheumNow

Very important. https://t.co/WjdMSsXc4S

• Jonathan Hausmann MD on Twitter: "Important to attract medical students to…

RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its faculty.

#ACR19 Review Course — Update in RA Therapy 2019 — Dr. Michael Weinblatt. My notes in thread ⬇️⬇️⬇️

From CORRONA registry- TCZ plus MTX similar drug survival compared to TBF plus MTX in TNFIR https://t.co/iDdYIoBlWo @RheumNow #ACR19

• PDF Viewer

OLE data shows Tx with Sarilumab improved likelihood of glucocorticoid dose reduction with 16% able to discontinue @RheumNow #ACR19 https://t.co/YWetjp5Rlp

• http://www.adelphi-e-solutions.com/system/files/SA21792%20ACR%20Steroid%20reduc…

Should we measure vit D in all pregnant women with SLE? As in general population low vitamin D increased miscarriage and preterm births. Weird as so did high vitamin D. Abstr 2531 #ACR #ACR19 @RheumNow #SLE #sle https://t.co/Mwb3WoCyBA

@Drbeckyg featured in the ACR Rheumatology Round-up!! Makes us think about how we might engage patients better in their disease assessment... #ACR19 ABST1366 @RheumNow https://t.co/47DfV7RH1s https://t.co/MZarkQkDdb

• Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Ac…
• Pat Rich on Twitter: "New Zealand study profiled looking at self-joint cou…